Quatiepine, an effective atypical anti psychotic administered as fumarate or hemifumarate
salts by intravenous injection shows poor brain uptake due to low partitioning and/or Pgp …

Quetiapine fumarate (QF) is an atypical antipsychotic, undergoing extensive first pass
metabolism and hence shows lower bioavailability orally. Solid Lipid Nanoparticles (SLNs) …

Quetiapine fumarate is an antipsychotic drug with poor oral bioavailability (9%) due to first‐
pass metabolism. Present work is an attempt to improve oral bioavailability of quetiapine …

Aims: The study aimed at developing and characterizing Nanostructured Lipid Carriers
(NLC) of Quetiapine Fumarate (QF) by Design of Experiment (DoE) for the enhancement of …

Background: Quetiapine fumarate, a 2nd generation anti-psychotic drug has oral
bioavailability of 9% because of hepatic first pass metabolism. Reports suggest that co …

The aim of present study is to investigate the potential of nanostructured lipid carriers (NLCs)
in improving the oral bioavailability of quetiapine fumarate, a second-generation …

Quetiapine fumarate is an atypical antipsychotic drug to treat schizophrenia. It has poor oral
bioavailability (9%) owing to its extensive first-pass metabolism. In the present study …

The current study intended to develop a new treatment of schizophrenia having a sustained
release activity. Quetiapine fumarate (QF)-loaded polymer/lipid hybrid nanoparticulate …

Background: The present study compares the efficacy of quetiapine fumarate (QF) and QF-
loaded solid lipid nanoparticles (QFSLN) as antipsychotic drugs for schizophrenia. Methods …

This study aims to investigate the changes in plasma pharmacokinetics and liver and brain
distribution of quetiapine (QTP) due to its encapsulation into a polymeric nanocarrier. For …